EATG » Immune response

Immune response

Argos announces issuance of patent covering the foundation for manufacturing its HIV immunotherapy

Patent related to strain-independent amplification of HIV nucleic acid sequences DURHAM, N.C., Feb. 15, 2018 -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of…

Promising drug target could restore immune system’s ability to fight HIV

Scientists in NCI’s Center for Cancer Research have identified a new target for drugs that could help people who are HIV-positive eliminate recalcitrant pools of the virus. The research findings…

How viruses disarm the immune system

Discovery of molecular mechanism could point toward new targets for treating patients How do viruses that cause chronic infections, such as HIV or hepatitis C virus, manage to outsmart their…

Recruiting natural killer cells to target HIV persistence

An important goal in HIV cure research is the identification of immune responses that might be induced or enhanced to promote clearance of virus-infected cells. The main focus of this…

Novel genomic tools provide new insight into human immune system

When the body is under attack from pathogens, the immune system marshals a diverse collection of immune cells to work together in a tightly orchestrated process and defend the host…

Antibodies show effectiveness for HIV prevention and promise for treatment and cure

The ability of HIV to mutate has been a major challenge to vaccine development. As the body produces antibodies to target the outer HIV envelope protein, this protein changes, thwarting…

Suboptimal ART adherence associated with greater inflammation in patients with HIV

Recently published findings indicate that suboptimal adherence to ART is associated with activation of coagulation and enhanced residual inflammation among patients with HIV, even if patients have already achieved virologic…

Selective suppression of inflammation could deplete HIV and control HIV activation

A class of anti-inflammatory drugs already FDA-approved for rheumatoid arthritis could “purge” the reservoir of infected immune cells in people infected by HIV, according to new research. When culturing cells…

CATIE: December 2017 issue of TreatmentUpdate now online

TreatmentUpdate is CATIE’s flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 223: Inflammation and HIV, December 2017 issue is available at: http://www.catie.ca/en/treatmentupdate/treatmentupdate-223

Baseline CD4 count biggest factor in long-term immune system improvements after starting HIV therapy

Pre-treatment CD4 cell count is the most important factor in immune recovery following the initiation of combination antiretroviral therapy (cART), according to the results of a large observation study published…